New drug shrinks thyroid tumors before surgery in early trial
NCT ID NCT04759911
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 33 times
Summary
This study tests whether taking selpercatinib before surgery can shrink thyroid tumors that have a specific genetic change (RET alteration). About 30 people with advanced or recurrent thyroid cancer will receive the drug before their operation. The goal is to make surgery more effective and help control the disease long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND ANAPLASTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Michigan Health Systems
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.